Dr Shirley D'Sa

Dr Shirley D'SaTel: 0203 447 7101
Fax: 020 3447 9911
Email: uclh.wmpoemsadminteam@nhs.net

University College Hospital

Myeloma, Blood Diseases (clinical haematology), Waldenström's macroglobulinemia

Professional background

Dr D'Sa is a haematologist with a specialist interest in Waldenström’s macroglobulinaemia and associated disorders, myeloma and POEMS syndrome, working both at University College London Hospitals NHS Foundation Trust, London and the Mount Vernon Cancer Centre, Northwood. She has weekly specialist clinics in Waldenström’s Macroglobulinaemia, Myeloma and Lymphoma and well as monthly Joint Neuropathy/POEMS Clinics with Dr Michael Lunn at the National Hospital for Neurology and Neurosurgery, London. Dr D’Sa has worked with patients and colleagues to set up an not-for-profit organisation called WMUK (www.wmuk.org.uk), which seeks to bring health professionals and patients closer together to challenge the barriers faced by patients with Waldenström’s Macroglobulinaemia, including the organisation of patient seminars for patients from across the UK and beyond. She is a co-author of the recently published UK WM Treatment Guidelines 2014 under the auspices of the British Committee for Standards in Haematology and has recently been awarded a grant by WMUK to set up a WM Biobank and Registry at UCLH which will be linked to the development of the Rory Morrison WMUK online Clinical Registry which will store UK clinical data for Waldenström's macroglobulinaemia  and closely associated B-cell malignancies. Dr D’Sa is working with Colleagues in the WMUK Doctors’ Forum to develop a blueprint for clinical trials in the UK, with a view to improving the understanding of the biology of WM as well as access to novel therapeutic agents.

Research interests

Dr D’Sa has a background in laboratory research into the recovery of immune function following allogeneic stem cell transplantation in myeloma patients.

Currently her research is clinically orientated and comprises clinical trials in the field of Waldenström’s macroglobulinaemia, myeloma and other lymphomas, including Phase I, II and II trials of novel therapies.

With colleagues in WMUK, in particular Dr Helen McCarthy (Bournemouth) she is seeking to capture an accurate picture of Waldenstroms in the UK through national Registry project, as well as developing the WM Biobank at the UCL Cancer Institute as a basis for bench to bedside projects, in collaboration with (inter)national colleagues.


  1. D'Sa S, Verfuerth S, Vyas P, et al. Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD. Bone marrow transplantation 1999;23(7):695-6 doi: 10.1038/sj.bmt.1701636[published Online First: Epub Date]|.
  2. D'Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. British journal of haematology 2003;123(2):309-22
  3. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(4):257-65 doi: 10.1053/bbmt.2003.50009[published Online First: Epub Date]|.
  4. Peggs KS, Verfuerth S, D'Sa S, et al. Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. British journal of haematology 2003;120(1):154-65
  5. D'Sa S, Yong K, Kyriakou C, et al. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. British journal of haematology 2004;125(6):756-65 doi: 10.1111/j.1365-2141.2004.04981.x[published Online First: Epub Date]|.
  6. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British journal of haematology 2005;130(3):363-72 doi: 10.1111/j.1365-2141.2005.05603.x[published Online First: Epub Date]|.
  7. Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British journal of haematology 2005;129(6):763-70 doi: 10.1111/j.1365-2141.2005.05521.x[published Online First: Epub Date]|.
  8. Quinn JP, Mohamedbhai S, Chipperfield K, et al. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leukemia & lymphoma 2008;49(10):1995-8 doi: 10.1080/10428190802340192[published Online First: Epub Date]|.
  9. Saifee TA, Elliott KJ, Rabin N, et al. Bortezomib-induced inflammatory neuropathy. Journal of the peripheral nervous system : JPNS 2010;15(4):366-8 doi: 10.1111/j.1529-8027.2010.00287.x[published Online First: Epub Date]|.
  10. Sellar RS, Corbett EL, D'Sa S, et al. Treatment for lymph node tuberculosis. Bmj 2010;340:c63 doi: 10.1136/bmj.c63[published Online First: Epub Date]|.
  11. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. British journal of haematology 2011;154(1):32-75 doi: 10.1111/j.1365-2141.2011.08573.x[published Online First: Epub Date]|.
  12. El-Sharkawi D, Basu S, Ocampo C, et al. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leukemia & lymphoma 2012;53(10):1949-52 doi: 10.3109/10428194.2012.679360[published Online First: Epub Date]|.
  13. Morrow JM, D'Sa S, Page RA, et al. Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia. Journal of neurology 2012;259(3):571-3 doi: 10.1007/s00415-011-6217-4[published Online First: Epub Date]|.
  14. Rabin N, Percy L, Khan I, et al. Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. British journal of haematology 2012;158(4):499-505 doi: 10.1111/j.1365-2141.2012.09188.x[published Online First: Epub Date]|.
  15. Groeneveldt L, Mein G, Garrod R, et al. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC cancer 2013;13:31 doi: 10.1186/1471-2407-13-31[published Online First: Epub Date]|.
  16. Moore S, Atwal S, Sachchithanantham S, et al. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. European journal of haematology 2013;90(5):420-5 doi: 10.1111/ejh.12070[published Online First: Epub Date]|.
  17. Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. International journal of laboratory hematology 2013 doi: 10.1111/ijlh.12097
  18. Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol. 2014 Feb 15. doi: 10.1111/bjh.12760. [Epub ahead of print]
  19. Marzolini MA, Thomson KJ, Dorman J, D'Sa S.  BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience. Bone Marrow Transplant. 2014 Sep;49(9):1231-2. doi: 10.1038/bmt.2014.113. Epub 2014 Jun 2.
  20. Morgane Pihan, Michael Lunn, Shirley D'Sa, Kwee Yong, Andrew Church and Mary Reilly. RAISED VEGF: USEFULNESS IN THE DIAGNOSIS OF POEMS SYNDROME. Journal of Neurology Neurosurgery & Psychiatry 09/2014; 85(10):e4-e4. DOI:10.1136/jnnp-2014-309236.181
  21. Jorge J Castillo, Shirley D'Sa, Michael P Lunn, Monique C Minnema, Alessandra Tedeschi, Frederick Lansigan, M Lia Palomba,  Marzia Varettoni, Ramon Garcia-Sanz, Lakshmi Nayak, Eudocia Q Lee, Mikael L Rinne, Andrew D Norden, Irene M Ghobrial and Steven P Treon. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. British Journal of Haematology 12/2015; DOI:10.1111/bjh.13883.
  22. Paul Maciocia, Mohsin Badat, Simon Cheesman, Shirley D'Sa, Rahul Joshi, Jonathan Lambert, Sajir Mohamedbhai, Martin Pule, David Linch and Kirit Ardeshna. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. British Journal of Haematology. 12/2015; DOI: 10.1111/bjh.13867
  23. Aisling Carr, Zane Jaunmuktane, Sebastian Brandner, J Kothari, Julian Blake, Shirley D'Sa and Mike Lunn. THE NEUROPATHY SPECTRUM IN Waldenström’s MACROGLOBULINAEMIA. Journal of Neurology Neurosurgery & Psychiatry 11/2015; 86(11):e4.60-e4. DOI:10.1136/jnnp-2015-312379.152 
  24. Aisling Carr, Shirley D'Sa,  A Arasaretnam, K Boyd, R Johnston, Zane Jaunmuktane, Sebastian Brandner, T Marafioti, Martin Koltzenburg, Mike Lunn. PERIPHERAL NERVE BING-NEEL SYNDROME. Journal of Neurology Neurosurgery & Psychiatry 11/2015; 86(11):e4.59-e4. DOI:10.1136/jnnp-2015-312379.151

GMC/GDC number: 3331633